

1

2

## Pioneer factor Pax7 initiates two-step cell-cycle dependent chromatin opening

3

4

5 Arthur Gouhier<sup>1,2</sup>, Justine Dumoulin-Gagnon<sup>1</sup>, Vincent Lapointe-Roberge<sup>1,2</sup>, Aurelio Balsalobre<sup>1</sup>  
6 and Jacques Drouin<sup>1,2,3\*</sup>

7

8 <sup>1</sup> Laboratoire de génétique moléculaire, Institut de recherches cliniques de Montréal (IRCM)

9 Montréal, Québec, H2W 1R7 Canada

10 <sup>2</sup> Department of Biochemistry, McGill University, Montreal, Quebec, Canada.

11 <sup>3</sup> Département de Biochimie, Université de Montréal, Montréal, Québec, Canada.

12

13 Word count: 2618 / 2500

14

15 **\*Corresponding author:** Jacques Drouin

16 Laboratoire de génétique moléculaire

17 Institut de recherches cliniques de Montréal (IRCM)

18 110, avenue des Pins Ouest

19 Montréal QC H2W 1R7 Canada

20 Tel.: (514) 987-5579; Fax: (514) 987-5575

21 [jacques.drouin@ircm.qc.ca](mailto:jacques.drouin@ircm.qc.ca)

## 22 **Summary**

23 Pioneer transcription factors direct cell differentiation by deploying new enhancer repertoires  
24 through their unique ability to target and initiate remodelling of closed chromatin. The initial steps  
25 of their action remain undefined although pioneers were shown to interact with nucleosomal target  
26 DNA and with some chromatin remodelling complexes. We now define the sequence of events  
27 that provide pioneers with their unique abilities. Chromatin condensation exerted by linker histone  
28 H1 is the first constraint on pioneer recruitment, and this establishes the initial speed of chromatin  
29 remodelling. The first step of pioneer action involves recruitment of the LSD1 H3K9me2  
30 demethylase for removal of this repressive mark, as well as recruitment of the MLL complex for  
31 deposition of the H3K4me1 mark. Further progression of pioneer action requires passage through  
32 cell division, and this involves dissociation of pioneer targets from perinuclear lamins. Only then,  
33 the SWI/SNF remodeling complex and the coactivator p300 are recruited, leading to nucleosome  
34 displacement and enhancer activation. Thus, the unique features of pioneer actions are those  
35 occurring in the lamin-associated compartment of the nucleus. This model is consistent with much  
36 prior work that showed a dependence on cell division for establishment of new cell fates.

37

## 38 **Introduction**

39 Cell fates are established and maintained through the action of specific combinations of  
40 transcription factors, including cell-restricted factors that define unique cell identities. The  
41 implementation of new cell fates relies on activation of new enhancer repertoires and this is  
42 achieved by pioneer transcription factors through their unique ability to access target sites in  
43 closed chromatin and trigger chromatin opening<sup>1</sup>. Many aspects of this general scheme remain  
44 undefined, notably pioneer interaction with closed chromatin and the initial events of chromatin  
45 remodelling<sup>1</sup>.

46 Investigation of DNA sequences targeted for pioneer action did not show preferential occurrence  
47 of sequence subsets, with some pioneers exhibiting degenerate recruitment sites<sup>2</sup> while others  
48 have stronger recruitment at pioneered sites<sup>3,4</sup>. Closed chromatin access may include the ability  
49 to bind target DNA sequences on nucleosomes, one of the earliest features ascribed to many,  
50 but not all<sup>5</sup>, pioneer factors<sup>6</sup>. Structural evidence suggests that pioneer binding may weaken the  
51 interaction of DNA with nucleosomes and hence contribute to initial chromatin alteration<sup>7-9</sup>. This  
52 is compatible with the appearance of so-called “accessible nucleosome conformation” caused by  
53 FOXA recruitment<sup>10</sup> or by subtle chromatin rearrangements that precede frank chromatin opening  
54 following the action of the pioneer Pax7 (REF.<sup>3</sup>). However, nucleosomal organisation cannot on  
55 its own explain barriers to pioneer action, and the data rather suggest that chromatin environment  
56 dictates whether chromatin is permissive or not for pioneer action. For example, the highly  
57 compacted constitutive heterochromatin prevents pioneer access<sup>11,12</sup>. The nature of crucial  
58 events initiating pioneer action remain elusive<sup>1</sup>.

59 It is likely that chromatin remodelling complexes identified for their role in development or in  
60 transcription are also involved in chromatin opening by pioneer factors. For example, the MLL  
61 complex is recruited to FOXA-pioneered sites that are targets of the oestrogen receptor in breast  
62 cancer cells<sup>13</sup>. Another pioneer, Pax7, interacts with the methyltransferase CARM1 and the  
63 MLL1/2 proteins<sup>14</sup>. The pioneers OCT4, GATA3 and ISL1, interact with Brg1, the ATPase of the  
64 SWI/SNF chromatin-remodelling complex<sup>15-17</sup>. But it is presently unclear how and when these  
65 interactions may be relevant to pioneer-dependent chromatin opening.

66 In the present study, we used an inducible system to define the time course of chromatin opening  
67 at Pax7-pioneered enhancers<sup>3</sup>. Amongst its different roles<sup>18</sup>, Pax7 specifies the intermediate  
68 pituitary melanotrope cell fate by opening a repertoire of >2000 enhancers<sup>3,19</sup>. While Pax7 is  
69 necessary to trigger chromatin opening, it also requires cooperation with the nonpioneer  
70 transcription factor Tpit to fully open and activate enhancer chromatin<sup>20</sup>. We now show that Pax7

71 pioneer action occurs in two steps, a first step that is limited by Pax7 recruitment strength and  
72 inversely correlated with the level of linker histone H1. And a second step that requires passage  
73 through replication and cell division, for recruitment of the SWI/SNF complex, nucleosome  
74 displacement and enhancer activation. This sequential scheme of pioneer action defines a  
75 conceptual framework to further probe and control the pioneering process.

76

## 77 **Results**

### 78 **Pax7 primes enhancers for activation**

79 We previously provided an exhaustive analysis of chromatin opening by the pioneer factor Pax7  
80 at two enhancer repertoires, one where Pax7 action results in complete enhancer activation and  
81 another where enhancers only reach the primed state<sup>3</sup>. To study the kinetics of enhancer opening  
82 by Pax7, we used a tamoxifen-inducible ER-Pax7 chimera system (Fig. 1a). The present study  
83 compared subsets of enhancers that are either activated or primed in response to Pax7 with a set  
84 of constitutively active enhancers where Pax7 binding does not alter chromatin organization (Fig.  
85 1b and Supplementary Fig. 1a, b). Having previously observed rapid Pax7 binding to pioneered  
86 sites in closed chromatin but relatively slower remodelling<sup>3</sup>, we first assessed whether the primed  
87 state is indeed a transitory state towards complete enhancer activation. The status of pioneered  
88 enhancers was assessed by ChIP-Seq for the chromatin mark histone monomethylated histone  
89 H3 Lys4 (H3K4me1) at different times following activation of ER-Pax7 (Fig. 1c). Thus, pioneered  
90 enhancers are observed first (12h) in the primed state followed by complete activation (Fig. 1c).  
91 The primed state was previously documented as presenting with a weak single peak of H3K4me1,  
92 whereas fully activated enhancers present with a stronger bimodal distribution of H3K4me1 that  
93 reflects nucleosome displacement at the center of pioneered enhancers<sup>1</sup>.

### 94 **Pioneered sites are heterogeneous**

95   ChIP-Seq analyses of pioneered sites show significant heterogeneity with regards to Pax7  
96   recruitment and deposition of chromatin marks (Fig. 1b). To assess the variability in  
97   implementation of Pax7 chromatin opening, we selected a panel of 14 pioneered sites  
98   representative of the Pax7 recruitment distribution (Fig. 1d). We validated that pioneered  
99   enhancers are first remodelled into a primed state by H3K4me1 ChIP-qPCR using two sets of  
100   primers, one centered on the Pax7 binding site and another shifted to one of the H3K4me1  
101   bimodal deposition summit: indeed, H3K4me1 central deposition (average half-time of 24h)  
102   occurs before lateral (average half-time of 32h) accumulation (Fig. 1e,f). Prior data had  
103   suggested interaction between Pax7 and the MLL complex that has H3K4me1 methyltransferase  
104   activity<sup>14</sup>. We therefore assessed MLL complex recruitment at Pax7 pioneered enhancers by  
105   ChIP-qPCR for the MLL3/4 and Ash2 components of the MLL complex: both MLL4 and Ash2 are  
106   recruited with a half-time (average of the 14 sites) of ~12 hours following Pax7 activation (Fig. 1f  
107   and Supplementary Fig. 1c). This half-time corresponds to a time when enhancers are in a primed  
108   state (Fig. 1c) and precedes bulk H3K4me1 deposition (Fig.1f). This delay taken together with the  
109   prior demonstration of a delay between chromatin opening measured by ATAC-Seq and Pax7  
110   recruitment<sup>3</sup> suggests that chromatin opening initiated by Pax7 may involve sequential steps.

### 111   **Chromatin opening occurs in two steps**

112   To assess the sequence of events leading to chromatin opening, we performed ChIP-qPCR time  
113   courses for various chromatin state markers and chromatin remodellers (Fig. 2a-d). Pax7  
114   recruitment itself has an average half-time of ~12 hours and we found a similar time course for  
115   recruitment of Tpit, a cooperating transcription factor that is required for chromatin opening at the  
116   Pax7 pioneered enhancers<sup>20</sup> (Fig. 2a). Recruitment of these factors parallels MLL4 and Ash2  
117   recruitment: they all precede deposition of H3K4me1 at the center of enhancers (Fig. 2a). We  
118   next assessed chromatin opening by ATAC-qPCR: the half-time of chromatin opening of ~24  
119   hours is similar to H3K4me1 deposition (Fig. 2b). These longer time courses are similar to those

120 of nucleosome displacement at these enhancers as revealed by ChIP-qPCR for histone H3 and  
121 for recruitment of Brg1 (Fig. 2b). The recruitment of the SWI/SFN complex (Brg1) occurs in parallel  
122 with recruitment of the general coactivator and histone acetylase p300 and of the cohesin complex  
123 protein SMC1 (Fig. 2b). These precede deposition of the active enhancer mark H3K27ac (Fig.  
124 2c). These time courses clearly identify two steps in Pax7-dependent chromatin opening: an initial  
125 step marked by Pax7 recruitment and a delayed second step that involves nucleosome  
126 displacement (Fig. 2a-c and Supplementary Fig. 2a, b).

127 We previously showed depletion of the repressive histone mark H3K9me2 that is typical of  
128 facultative heterochromatin at the Pax7 pioneered enhancers<sup>3</sup>. We next assessed the time course  
129 of this depletion and observed a half-time of ~12 hours (Fig. 2d). Since facultative heterochromatin  
130 is compacted, we assessed the levels of linker histone H1 at these sites and observed a time  
131 course of H1 depletion similar to that of H3K9me2 depletion (Fig. 2d). The initiation of Pax7  
132 pioneering thus correlates with an initial perturbation of the chromatin environment represented  
133 by the loss of linker histone H1 and the loss of the facultative heterochromatin mark H3K9me2,  
134 together with implementation of the primed state reflected by a weak deposition of H3K4me1 (Fig.  
135 1c).

136

### 137 **Pioneering kinetics depend on Pax7 recruitment strength**

138 While the average time response curves defined two steps in the pioneering process, examination  
139 of parameters for the individual 14 pioneer sites revealed heterogeneity in the kinetics of pioneer  
140 action (Fig. 2e). Color-coded individual time course curves for Pax7 recruitment, histone H3  
141 depletion, ATAC signal, H3K4me1 deposition, Brg1 recruitment and H3 depletion indicate that  
142 the stronger Pax7 recruitment sites (Fig. 1d, red) are remodelled quicker than the weaker sites  
143 (blue). The correlation between recruitment strength and half-time of remodelling is observed for

144 all parameters (Fig. 2f). Similar correlations are observed for all pioneered enhancers genome-  
145 wide (Supplementary Fig. 3a). Computation of time course curves for the five strongest and five  
146 weakest sites indicates an average delay of ~6 hours between the two subgroups (Supplementary  
147 Fig. 3b). These data clearly support the conclusion that recruitment strength determines the onset  
148 of chromatin remodelling at pioneered sites.

149 To assess whether these correlations relate to long-term or initial levels of Pax7 recruitment, we  
150 performed similar comparisons at 1 hour after Pax7 activation. These revealed that recruitment  
151 strength at 1 and 48 hours are directly correlated (Fig. 2g and Supplementary Fig. 4) and that  
152 initial recruitment is inversely correlated with the time course of chromatin remodelling (Fig. 2h).

153 We next assessed the impact of initial chromatin organization on the strength of Pax7 recruitment.  
154 Whereas nucleosome content reflected by total histone H3 ChIP levels and the level of the  
155 repressive mark H3K9me2 (Supplementary Fig. 5a) do not correlate with Pax7 recruitment,  
156 chromatin compaction dependent on linker histone H1 determines the initial (1h) strength of Pax7  
157 recruitment (Fig. 2i). Similar observations were made at 48h after Pax7 activation (Supplementary  
158 Fig. 5b) and confirmed genome-wide by UMAP representation of Pax7 recruitment compared to  
159 histone H1 levels (Fig. 2j). Hence, the higher the level of histone H1, the weaker the initial Pax7  
160 recruitment and the longer it takes to remodel these sites (Fig. 2i). In summary, chromatin  
161 condensation reflected by the level of histone H1 constrains Pax7 recruitment and determines the  
162 time course of chromatin remodelling.

### 163 **Activation of Pax7 primed enhancers requires cell division**

164 The half-time of the second step of the pioneering process (~24 hours) corresponds roughly to  
165 the half-time for AtT-20 cell division. Thus, the second step of the pioneering process may require  
166 DNA replication or passage through cell division. We assessed this by blocking AtT-20 cell  
167 replication for 12 hours with mimosine (Fig. 3a, b). Mimosine-blocked AtT-20 cells are viable and

168 can re-enter cell cycle upon release (Supplementary Fig. 6a). We assessed each step of the  
169 pioneering process by comparison of mimosine-blocked with normal cycling cells. These  
170 experiments indicate that Pax7 recruitment and H3K9me2 depletion, two parameters of the first  
171 pioneering step, occur independently of cell replication and division (Fig. 3c). In marked contrast,  
172 all marks of the second step of the pioneering process are blocked by mimosine treatment,  
173 including chromatin opening assessed by ATAC-qPCR, Brg1 and p300 recruitment, and  
174 deposition of H3K27ac (Fig. 3d and Supplementary Fig. 6b). Since prior experiments showed that  
175 the first step of the pioneering process yields enhancers in the primed state, we assessed the  
176 pattern of H3K4me1 in mimosine-blocked cells that fail to undergo the second step of the  
177 pioneering process. The CHIP-Seq average profiles of pioneered enhancers in mimosine-blocked  
178 cells remain in the primed state (Fig. 3e) in contrast to normal cycling cells that are in the activated  
179 state at a similar time following Pax7 activation (Fig. 1c).

#### 180 **Cell division is required for dissociation from nuclear lamins**

181 Since the first change observed in parallel with Pax7 recruitment is the depletion of the repressive  
182 mark H3K9me2, we queried a putative mechanism for this depletion. The analysis of proteins  
183 associated with Pax7 in RIME experiments<sup>21</sup> provided two candidate demethylases, KDM1A  
184 (LSD1) and KDM3A (Harris et al. In preparation). Hence, we assessed recruitment of these  
185 demethylases at Pax7 pioneered enhancers and found that KDM1A is recruited with a half-time  
186 corresponding to step 1 of the process (Fig. 4a) whereas KDM3A is recruited at step 2 of the  
187 process (Supplementary Fig. 7a). The early loss of H3K9me2 may be a mechanism to alter the  
188 localization of pioneered sites in the nucleoplasm. Indeed, H3K9me2-marked loci are found in the  
189 nuclear periphery B compartment and their localization is altered by removal of H3K9me2  
190 (REF.<sup>22</sup>). We thus assessed the association of the Pax7 pioneered sites with lamin B1, a marker  
191 of the nuclear B compartment (Fig. 4b) and found that high levels of lamin B1 correlated with high  
192 levels of H3K9me2 at pioneered sites (Fig. 4c). Despite the loss of H3K9me2 at step 1, we



193 observed dissociation of pioneered sites from lamin B with a half-time corresponding to the cell  
194 cycle-dependent second step (Fig. 4a). If the requirement for cell division observed for step two  
195 of the pioneering process depends on nuclear compartment switching, the blockade of cell  
196 division should prevent dissociation from lamin B, and this is indeed what was observed in  
197 mimosine-blocked cells (Fig. 4d). In this context, we would expect that enhancers that are de  
198 novo primed by Pax7 would not show significant H3K9me2 depletion as is indeed observed (Fig.  
199 4e). We surmise that the slight decrease of H3K9me2 at primed sites is not sufficient for  
200 compartment switching and this is supported by the similar levels of H3K9me2 at sites that are  
201 were already in the primed state before Pax7 activation and that get transcriptionally activated by  
202 Pax7 (Activated enhancers, Fig. 4e). Further, we observe recruitment of the SWI/SNF complex  
203 only after full activation but not with the primed state as revealed by Brg1 ChIP-Seq (Fig. 4e), in  
204 agreement with restricted nuclear localisation of Brg1 in the central nucleoplasm<sup>23</sup>. We found  
205 similar features for recruitment of RNA Pol II and components (MED1 and MED12) of the Mediator  
206 complex (Supplementary Fig. 7b). Why do some enhancers fail to complete the process of  
207 activation? A failure to recruit an essential cooperating transcription factor could be responsible  
208 and indeed, we observe no recruitment of Tpit, a nonpionner factor required for full activation of  
209 melanotrope enhancers<sup>20</sup>, at de novo primed sites (Fig. 4e).

210 In conclusion, and taken collectively, the present data suggest a model for pioneer factor action  
211 (Fig. 4f, g) in which the first steps are compatible with actions within the perinuclear compartment  
212 B: these include removal of repressor marks together with deposition of activation marks  
213 corresponding to the primed state. The ensuing steps for enhancer opening require passage  
214 through cell division that allows for lamin dissociation, and presumably switching to the A  
215 compartment, where the loci become accessible to the SWI/SNF complex for nucleosome  
216 displacement and transcriptional activation.

217

## 218 Discussion

219 The present work shows that chromatin compaction elicited by histone H1 determines the strength  
220 of pioneer Pax7 recruitment and speed of its actions. Beyond this limiting step, the different  
221 parameters of chromatin opening follow a similar time course while the next limiting step is  
222 imposed by cell division and its importance for lamin, and presumably compartment B,  
223 dissociation (Fig. 4g). The association of SWI/SNF (Brg1) recruitment and nucleosome  
224 displacement is consistent with the nuclear sublocalization of BRG1 and Brm in compartment A,  
225 but not in the perinuclear compartment B, of the nucleoplasm<sup>23</sup>.

226 As the ability of loci to switch from compartments B to A depends on the level of H3K9me2 (REF.<sup>22</sup>  
227 <sup>24</sup>), it follows that enhancers that are primed (but not activated) by Pax7 do not show significant  
228 H3K9me2 depletion (Fig. 4e). In contrast, these primed enhancers have deposition of H3K4me1  
229 presenting as a single weak peak (Fig. 4f). Consistent with an early recruitment of the MLL  
230 complex (Fig. 2a), the data indicate that targeted enhancers can be primed in the lamin-  
231 associated compartment including deposition of H3K4me1. The limiting factor for complete  
232 enhancer activation is thus controlled by demethylation of H3K9me2 and this appears to require  
233 the cooperating nonpioneer Tpit (Fig. 4e). The variable effectiveness of Pax7 to open chromatin  
234 at different sites may thus be related to chromatin constraints such as dictated by histone H1,  
235 and/or to the relative affinity for DNA binding sites and/or to nonpioneer interaction. In models that  
236 may involve different cooperating nonpioneers, a single pioneer factor may thus implement  
237 various subsets of primed enhancers ready for activation in response to an array of developmental  
238 or signaling cues mediated through the activities of different nonpioneers.

239

240

## References

241

- 242 1 Balsalobre, A. & Drouin, J. Pioneer factors as master regulators of the epigenome and cell  
243 fate. *Nat Rev Mol Cell Biol* **23**, 449-464 (2022). [https://doi.org/10.1038/s41580-022-](https://doi.org/10.1038/s41580-022-00464-z)  
244 [00464-z](https://doi.org/10.1038/s41580-022-00464-z)
- 245 2 Soufi, A. *et al.* Pioneer transcription factors target partial DNA motifs on nucleosomes to  
246 initiate reprogramming. *Cell* **161**, 555-568 (2015).  
247 <https://doi.org/10.1016/j.cell.2015.03.017>
- 248 3 Mayran, A. *et al.* Pioneer factor Pax7 deploys a stable enhancer repertoire for specification  
249 of cell fate. *Nat Genet* **50**, 259–269 (2018). <https://doi.org/10.1038/s41588-017-0035-2>
- 250 4 Pelletier, A., Mayran, A., Omichinski, J. & Drouin, J. Pax7 Pioneer action requires both  
251 paired and homeo DNA binding domains. *Nucleic Acids Research*, 1–13 (2021).  
252 <https://doi.org/10.1093/nar/gkab561>
- 253 5 Minderjahn, J. *et al.* Mechanisms governing the pioneering and redistribution capabilities  
254 of the non-classical pioneer PU.1. *Nat Commun* **11**, 402 (2020).  
255 <https://doi.org/10.1038/s41467-019-13960-2>
- 256 6 Cirillo, L. A. *et al.* Binding of the winged-helix transcription factor HNF3 to a linker histone  
257 site on the nucleosome. *EMBO J* **17**, 244-254 (1998).  
258 <https://doi.org/10.1093/emboj/17.1.244>
- 259 7 Dodonova, S. O., Zhu, F., Dienemann, C., Taipale, J. & Cramer, P. Nucleosome-bound  
260 SOX2 and SOX11 structures elucidate pioneer factor function. *Nature* **580**, 669-672  
261 (2020). <https://doi.org/10.1038/s41586-020-2195-y>
- 262 8 Michael, A. K. *et al.* Mechanisms of OCT4-SOX2 motif readout on nucleosomes. *Science*  
263 **368**, 1460-1465 (2020). <https://doi.org/10.1126/science.abb0074>
- 264 9 Tanaka, H. *et al.* Interaction of the pioneer transcription factor GATA3 with nucleosomes.  
265 *Nat Commun* **11**, 4136 (2020). <https://doi.org/10.1038/s41467-020-17959-y>
- 266 10 Iwafuchi-Doi, M. *et al.* The Pioneer Transcription Factor FoxA Maintains an Accessible  
267 Nucleosome Configuration at Enhancers for Tissue-Specific Gene Activation. *Mol Cell* **62**,  
268 79-91 (2016). <https://doi.org/10.1016/j.molcel.2016.03.001>
- 269 11 Soufi, A., Donahue, G. & Zaret, K. S. Facilitators and impediments of the pluripotency  
270 reprogramming factors' initial engagement with the genome. *Cell* **151**, 994-1004 (2012).
- 271 12 Nicetto, D. *et al.* H3K9me3-heterochromatin loss at protein-coding genes enables  
272 developmental lineage specification. *Science* **363**, 294-297 (2019).  
273 <https://doi.org/10.1126/science.aau0583>
- 274 13 Jozwik, K. M., Chernukhin, I., Serandour, A. A., Nagarajan, S. & Carroll, J. S. FOXA1  
275 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase  
276 MLL3. *Cell Rep* **17**, 2715-2723 (2016). <https://doi.org/10.1016/j.celrep.2016.11.028>
- 277 14 Kawabe, Y., Wang, Y. X., McKinnell, I. W., Bedford, M. T. & Rudnicki, M. A. Carm1  
278 regulates Pax7 transcriptional activity through MLL1/2 recruitment during asymmetric  
279 satellite stem cell divisions. *Cell Stem Cell* **11**, 333-345 (2012).  
280 <https://doi.org/10.1016/j.stem.2012.07.001>
- 281 15 King, H. W. & Klose, R. J. The pioneer factor OCT4 requires the chromatin remodeller  
282 BRG1 to support gene regulatory element function in mouse embryonic stem cells. *Elife*  
283 **6** (2017). <https://doi.org/10.7554/eLife.22631>
- 284 16 Takaku, M. *et al.* GATA3-dependent cellular reprogramming requires activation-domain  
285 dependent recruitment of a chromatin remodeler. *Genome Biol* **17**, 36 (2016).  
286 <https://doi.org/10.1186/s13059-016-0897-0>

- 287 17 Gao, R. *et al.* Pioneering function of *Isl1* in the epigenetic control of cardiomyocyte cell  
288 fate. *Cell Res* **29**, 486-501 (2019). <https://doi.org/10.1038/s41422-019-0168-1>
- 289 18 Mayran, A., Pelletier, A. & Drouin, J. Pax factors in transcription and epigenetic  
290 remodelling. *Semin Cell Dev Biol* **44**, 135-144 (2015).  
291 <https://doi.org/10.1016/j.semcdb.2015.07.007>
- 292 19 Budry, L. *et al.* The selector gene *Pax7* dictates alternate pituitary cell fates through its  
293 pioneer action on chromatin remodeling. *Genes & Development* **26**, 2299-2310 (2012).  
294 <https://doi.org/10.1101/gad.200436.112>
- 295 20 Mayran, A. *et al.* Pioneer and nonpioneer factor cooperation drives lineage specific  
296 chromatin opening. *Nature Communications* **10**, 3807 (2019).  
297 <https://doi.org/10.1038/s41467-019-11791-9>
- 298 21 Mohammed, H. *et al.* Rapid immunoprecipitation mass spectrometry of endogenous  
299 proteins (RIME) for analysis of chromatin complexes. *Nat Protoc* **11**, 316-326 (2016).  
300 <https://doi.org/10.1038/nprot.2016.020>
- 301 22 Poleshko, A. *et al.* H3K9me2 orchestrates inheritance of spatial positioning of peripheral  
302 heterochromatin through mitosis. *Elife* **8** (2019). <https://doi.org/10.7554/eLife.49278>
- 303 23 Reyes, J. C., Muchardt, C. & Yaniv, M. Components of the human SWI/SNF complex are  
304 enriched in active chromatin and are associated with the nuclear matrix. *J Cell Biol* **137**,  
305 263-274 (1997). <https://doi.org/10.1083/jcb.137.2.263>
- 306 24 Smith, C. L., Poleshko, A. & Epstein, J. A. The nuclear periphery is a scaffold for tissue-  
307 specific enhancers. *Nucleic Acids Res* **49**, 6181-6195 (2021).  
308 <https://doi.org/10.1093/nar/gkab392>
- 309 25 Langlais, D., Couture, C. & Drouin, J. The Stat3/GR interaction code: predictive value of  
310 direct/indirect DNA recruitment for transcription outcome. *Molecular Cell* **47**, 38-49 (2012).  
311

312

313

314 **ACKNOWLEDGMENTS**

315 We are very grateful to Dr. Ali Shilatifard for the MLL3 and MLL4 antibodies, to Odile Neyret and  
316 Sarah Boisset for NGS analyses, and to Valérie Magoon for her expert secretarial assistance.  
317 Data analyses were possible thanks to the support of Compute Canada. This work was supported  
318 by Foundation grant FDN-154297 to J.D. from the Canadian Institutes of Health Research.

319 **AUTHOR CONTRIBUTIONS**

320 A.G. and J.D. conceived the study, A.G., A.B. and J.D. conceived and designed the experiments,  
321 A.G., J.D.-G. and V.L.-R. performed ChIP experiments, A.G. and J.D. wrote the manuscript.

322 **COMPETING INTERESTS**

323 The authors declare no competing financial interests.

324

325 **Legends to Figures**

326 **Fig. 1 | Pax7 primes enhancers for activation.** a) The role of Pax7 in specification of the  
327 intermediate pituitary melanotrope cell fate is illustrated in contrast to the corticotrope cell fate.  
328 These two hormone-secreting lineages express the same hormone precursor gene,  
329 proopiomelanocortin (POMC), and their fates are determined by the Tbox transcription factor Tpit.  
330 The mouse AtT-20 cells are a model of the corticotrope lineage and Pax7 expression reprograms  
331 these cells towards a melanotrope-like fate. b) Heat map representation of ChIP-Seq and ATAC-  
332 Seq data for three subsets of Pax7-targeted enhancers. Data are shown before (0h) and after  
333 48h induction of Pax7 activity in AtT-20 cells harbouring a tamoxifen-inducible ER-Pax7 chimera<sup>3</sup>.  
334 Pioneered enhancers have no marks before Pax7 activation and present with hallmarks of  
335 transcriptionally active enhancers after, namely appearance of an ATAC-Seq signal together with  
336 a bimodal distribution of H3K4me1 deposition. Pax7 primed enhancers also show appearance of  
337 weaker ATAC-Seq and H3K4me1 signals, the latter presenting as a single weak peak. Finally, a  
338 set of constitutively active enhancers serve as control for comparisons. These enhancers bind  
339 Pax7, but this binding is not associated with any change in chromatin signature. These enhancer  
340 subsets were previously described<sup>3,4</sup>. c) Average profiles of H3K4me1 deposition at subsets of  
341 Pax7-remodelled enhancers at indicated times following tamoxifen (Tam) activation of ER-Pax7.  
342 d) Selection of 14 Pax7-pioneered sites used for detailed investigation by qPCR and color-coded  
343 from red to blue according to strength of Pax7 recruitment. Pax7 and H3K4me1 ChIP-Seq, and  
344 ATAC-Seq, profiles are shown for these individual peaks at 48h following Pax7 activation. e) Time  
345 course of H3K4me1 deposition determined by ChIP-qPCR at the 14 pioneered sites illustrated  
346 above. For each site, a red curve illustrates H3K4me1 accumulation under the Pax7 peak  
347 (centered), whereas a blue curve represents H3K4me1 deposition over a lateral peak of  
348 deposition (shifted) that characterizes the bimodal H3K4me1 distribution of fully active enhancers.  
349 f) Average (of 14 pioneered sites) time course of H3K4me1 accumulation (centered and shifted)

350 is compared with ChIP-qPCR data for recruitment of two protein components of the MLL  
351 remodelling complex, MLL4 and Ash2. Data represent the means  $\pm$  sem of duplicate biological  
352 samples.

353 **Fig. 2 | Pax7-dependent chromatin opening occurs in two steps.** **a)** Average (14 pioneered  
354 sites of Fig.1d represented as means  $\pm$  sem of duplicate biological samples,  $n \geq 2$ ) profiles of  
355 ChIP-qPCR data for Pax7, Tpit, MLL4 and Ash2 that are recruited with a similar time course ( $T_{1/2}$   
356  $\sim 12$  hrs) compared to accumulation of H3K4me1 (center). **b)** Compared to Pax7 recruitment,  
357 ATAC-Seq signals and recruitment of Brg1, p300 and SMC1, together with depletion of Histone  
358 H3 occur with an average  $T_{1/2}$  of  $\sim 24$ h ( $n \geq 2$ ). **c)** Deposition of activation mark H3K27ac and  
359 bimodal H3K4me1 (shifted) are slightly delayed compared to ATAC signal ( $n \geq 2$ ). **d)** Depletion of  
360 the repressive mark H3K9me2 and of linker Histone H1 occur with a  $T_{1/2}$  of  $\sim 12$ h ( $n \geq 2$ ). **e)**  
361 Individual site ChIP-qPCR time course data for recruitment of Pax7, H3K4me1 and Brg1, together  
362 with time courses of ATAC signals and depletion histones H1 and H3 shown for the 14 pioneered  
363 sites color-coded (in Fig.1d) from red to blue to reflect the strength of Pax7 recruitment. **f)**  
364 Correlations between Pax7 recruitment strength and various markers depicted in (e). **g)**  
365 Correlation between rapid (1h) and long-term (48h) Pax7 recruitment strength. **h)** Inverse  
366 correlation between initial (1h) Pax7 recruitment strength and the average half-times of all  
367 markers of chromatin remodelling at the 14 pioneered sites. **i)** Correlations between the initial  
368 levels of histone H1 at the 14 pioneered sites and the strength of Pax7 recruitment and with the  
369 half-time of chromatin remodelling markers. **j)** UMAP representation of Pax7 recruitment strengths  
370 at the indicated times after Tam addition compared to initial histone H1 levels measured by ChIP-  
371 Seq at pioneered enhancers depicted in Fig. 1b.

372

373 **Fig. 3 | Activation of Pax7 pioneered enhancers requires cell division.** a) Experimental  
374 design for assessment of chromatin remodelling in cells with mimosine-blocked cell cycle  
375 compared to normally cycling cells. b) FACS profiles of normal (no mimosine) cells compared to  
376 cells incubated for 12h with mimosine that exhibit cell-cycle arrest in G1. Representative of n=2  
377 is shown. c) Both recruitment of Pax7 and depletion of H3K9me2 measured by ChIP-qPCR at the  
378 14 pioneered sites are not affected by blocking AtT-20 cell cycle with mimosine (n=2). d) In  
379 contrast, chromatin opening (ATAC) recruitments of Brg1, p300 and H3K27ac measured by ChIP-  
380 qPCR are all severely curtailed in mimosine-blocked cells (n=2). e) Average profiles of H3K4me1  
381 accumulation at Pax7-remodelled enhancer subsets measured by ChIP-Seq at different times  
382 after Tam activation of ER-Pax7.

383 **Fig. 4 | Pax7-dependent chromatin remodelling involves H3K9me2 demethylation and**  
384 **dissociation from lamins.** a) Average (14 pioneered sites of Fig.1d represented as means  $\pm$   
385 sem of duplicate biological samples) time courses for depletion of H3K9me2 and dissociation  
386 from lamin B1 measured by ChIP-qPCR compared to the time courses of recruitment for the  
387 H3K9me2 demethylase, KDM1A (LSD1). b) Pax7 pioneered sites have high levels of H3K9me2  
388 and lamin B1 before Pax7 action. c) Correlation between initial levels of H3K9me2 and lamin B1  
389 at 14 pioneered sites before Pax7 action (n  $\geq$  2). d) Lamin depletion is prevented by cell cycle  
390 blockade with mimosine (n=2). e) Heatmaps of ChIP-Seq profiles for Pax7, H3K4me1, H3K9me2,  
391 Tpit and Brg1 at subsets of Pax7 remodelled enhancers. Data for other markers presented in  
392 Supplementary Fig. 7. f) Schematic representation of proteins shown in the present work to be  
393 associated with either primed or active enhancer states. g) Sequential model of Pax7 pioneer  
394 action. Pax7 pioneer targets are enriched in H3K9me2 and associated with lamin B1, which is  
395 typical of chromatin that is present in the perinuclear B compartment. Step 1 of the pioneering  
396 process involves recruitment of the H3K9me2 demethylase KDM1A (LSD1), together with the  
397 MLL complex. These lead to demethylation of H3K9me2 and H3K4me1 deposition, respectively.



398 Cell cycle blockade with mimosine prevents Pax7-dependent remodelling from proceeding  
399 further. At mitosis, masking of the H3K9me2 mark by H3S10 phosphorylation accompanies  
400 dissociation of A and B compartments of the nucleus<sup>22</sup>. Following mitosis and nuclear reassembly,  
401 Pax7-pioneered targets that have undergone H3K9me2 demethylation will remain in the central  
402 nuclear A compartment where the Brg1 and Brm ATPase's of the SWI/SNF complex are  
403 localised<sup>23</sup> and recruited for nucleosome displacement and complete enhancer activation. Pax7  
404 primed enhancers do not recruit the cooperating nonpioneer factor Tpit and hence, the  
405 cooperation between Tpit and Pax7 appears required for significant H3K9me2 demethylation and  
406 continuation of the Pax7-dependent remodelling process to the cell cycle-dependent step 2.

407

408




Fig. 1 | Pax7 primes enhancers for activation.




Fig. 2 | Pax7-dependent chromatin opening occurs in two steps.




Fig. 3 | Activation of Pax7 pioneered enhancers requires cell division.




Fig. 4 | Pax7-dependent chromatin remodelling involves H3K9me2 demethylation and dissociation from lamins.